A deep-sea-derived, heat-resistant antimicrobial peptide with inhibitory effects on Vibrio.
By screening the antimicrobial peptide GigantinB from deep-sea shield snails, the problem of screening antimicrobial peptides in deep sea has been solved, achieving high efficiency inhibition and thermal stability against Vibrio, and promoting its application in aquaculture.
Patent Information
- Application Number
- CN202611568006.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-11
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to effectively screen for antimicrobial peptides with novel structures and application value, especially those derived from the deep sea. Furthermore, their application in aquaculture faces challenges, such as unresolved issues regarding antimicrobial activity, stability, and biosafety.
GigantinB, an antimicrobial peptide with an α-helical structure, was screened from the shield snail in deep-sea hydrothermal vents. It was prepared and purified by solid-phase chemical synthesis and confirmed to have excellent antibacterial activity against Vibrio and good thermal stability. It is suitable for use as an antimicrobial drug, feed additive, and immune enhancer in aquaculture animals.
The antimicrobial peptide GigantinB has a significant inhibitory effect on Vibrio parahaemolyticus, Vibrio alginolyticus, and Vibrio neocalidonia, and maintains its activity under high temperature conditions. It is suitable for use as an antimicrobial drug, feed additive, and immune enhancer in aquaculture, reducing the risk of antibiotic use.
Smart Images

Figure CN123106864A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of polypeptide application technology, specifically relating to a deep-sea-derived, heat-resistant antimicrobial peptide with an inhibitory effect on Vibrio. Background Technology
[0002] Aquaculture animals are susceptible to various pathogenic microorganisms during the farming process. Among them, Vibrio is a significant pathogen that harms the health of aquaculture animals and affects the stable development of the aquaculture industry. Currently, antibiotics and other antimicrobial drugs remain one of the important means of disease control in aquaculture. However, long-term or irrational use of antibiotics and other antimicrobial drugs can easily lead to drug residues in farmed animals, increased drug resistance in pathogenic microorganisms, and pollution of the aquaculture water environment, which may adversely affect the quality and safety of aquatic products and the aquaculture ecological environment. Therefore, developing novel antimicrobial substances with good antibacterial activity, safety, and application potential to reduce the dependence of aquaculture on traditional antibiotics is one of the urgent problems to be solved in the field of aquaculture disease control.
[0003] Antimicrobial peptides are a class of bioactive peptides with antimicrobial activity, typically characterized by diverse mechanisms of action and broad antimicrobial spectrum. Some antimicrobial peptides can also modulate host immune responses, promote growth, and improve overall health. Compared to traditional antibiotics, antimicrobial peptides show potential in reducing the risk of antibiotic resistance in pathogens and have attracted widespread attention in areas such as disease control in aquaculture, animal health management, and the development of antibiotic alternatives. However, the development and application of natural antimicrobial peptides still face certain limitations. For example, different antimicrobial peptides exhibit variations in antimicrobial activity, stability, and biosafety, and some may be affected by factors such as protease degradation, changes in environmental conditions, or preparation costs. Therefore, obtaining antimicrobial peptides with novel structures, good antimicrobial activity, and suitable application characteristics is a crucial foundation for promoting their application in aquaculture.
[0004] Vibrios are a class of bacteria widely distributed in aquatic environments. Among them, Vibrio parahaemolyticus is a Gram-negative halophilic bacterium that is not only an important pathogen causing foodborne diseases related to aquatic products, but can also infect various farmed aquatic animals, posing a threat to aquaculture production and aquatic product safety. Other Vibrios, such as Vibrio neocaledonicus and Vibrio alginolyticus, are also associated with bacterial diseases in some farmed aquatic animals, causing host tissue damage, abnormal immune responses, and even death through virulence factors and other pathogenic mechanisms. At the same time, climate warming and changes in the marine environment may affect the survival, reproduction, and geographical distribution of pathogenic Vibrios, thereby increasing the risk of Vibrio-related diseases in some areas (Baker-Austin, C., Trinanes, J., Taylor, N. et al. Emerging Vibrio risk at high latitudes in response to ocean warming. Nature Climate Change, 3: 73–77, 2013). Therefore, developing novel antibacterial substances with good antibacterial effects against various pathogenic Vibrio species is of great significance for reducing the risk of bacterial infection in aquatic animals, reducing antibiotic use, and ensuring the quality and safety of aquatic products.
[0005] Marine organisms have adapted to complex and ever-changing environmental conditions over a long period of time, developing diverse physiological adaptation and defense mechanisms through interactions with environmental microorganisms and other organisms. These mechanisms represent an important resource for discovering novel bioactive substances. In particular, special habitats such as deep-sea hydrothermal vents, characterized by high temperatures, unique chemical compositions, and complex microbial communities, may allow organisms to form bioactive molecules with special structures and biological functions.
[0006] Gigantopelta aegis is a gastropod mollusc distributed in the deep-sea hydrothermal vents of the Southwest Indian Ocean Ridge. It can establish symbiotic relationships with chemoautotrophic symbiotic microorganisms on its body surface or within its body, relying on these symbiotic systems to obtain some energy and carbon. Through long-term adaptation to the unique deep-sea environment and coexistence with a large number of microorganisms, Gigantopelta aegis possesses biological defense mechanisms worthy of study, and its related genetic resources may contain peptides with potential antimicrobial activity. Therefore, research on such organisms in unique habitats can help expand the resource sources of natural antimicrobial peptides and provide new research directions for obtaining structurally diverse and novel antimicrobial peptides.
[0007] However, screening novel antimicrobial peptides from natural biological resources remains technically challenging. On one hand, the number of potential antimicrobial peptide candidate sequences in organisms is large, with variations in sequence length, amino acid composition, charge distribution, and spatial conformation, making it difficult to accurately determine their actual antimicrobial activity based solely on sequence characteristics. On the other hand, the sequence information obtained from transcriptome sequencing may contain a large number of genes or transcripts not directly related to antimicrobial peptides. Even if candidate sequences are obtained through bioinformatics analysis, further confirmation of their coding relationships, mature peptide structures, and biological functions is still necessary. Furthermore, there may be discrepancies between the predicted results and actual antimicrobial effects of candidate peptides; their antimicrobial spectrum, minimum inhibitory concentration (MIC), stability, cytotoxicity, and applicability to aquaculture animals all require further verification. For antimicrobial peptides derived from organisms in special deep-sea habitats, the identification, activity evaluation, and application potential analysis of candidate peptides face additional challenges due to the relatively limited accumulation of relevant sequence resources and functional research. Therefore, how to effectively screen candidate antimicrobial peptides with practical antibacterial activity from complex biological sequence resources, and further identify antimicrobial peptides with novel structures and application value, is an important technical problem that needs to be solved in this field. Summary of the Invention
[0008] The purpose of this invention is to provide a deep-sea-derived, heat-resistant antimicrobial peptide with inhibitory effects on Vibrio. This antimicrobial peptide exhibits inhibitory activity against both Gram-positive and Gram-negative bacteria, and can inhibit pathogenic Vibrio species in aquatic animals (such as Vibrio parahaemolyticus, Vibrio alginolyticus, and Vibrio neocalidonia). Simultaneously, this antimicrobial peptide possesses high thermal stability, enabling it to better withstand the high-temperature processing involved in the production of aquatic animal feed additives or immunizing agents. The antimicrobial peptide Gigantin B of this invention has the potential to become an antibiotic alternative and shows promising application prospects in the aquaculture industry.
[0009] The present invention first provides an antimicrobial peptide GigantinB, the amino acid sequence of which is MLLKLLAVIKVMNMHLTQFLKVNSLIQQQARRKQKEKHL (SEQ ID No: 1).
[0010] This invention also protects the use of the aforementioned antimicrobial peptide GigantinB in the preparation of antimicrobial drugs, feed additives, and immune enhancers.
[0011] In another aspect, the present invention provides an antimicrobial article comprising the above-mentioned antimicrobial peptide Gigantin B or its derivative peptide.
[0012] The antimicrobial peptide Gigantin B of this invention exhibits excellent antibacterial activity against Vibrio parahaemolyticus, Vibrio alginolyticus, and Vibrio neocalidonia. At a concentration of 0.32 mM, it significantly inhibits Vibrio parahaemolyticus and Vibrio neocalidonia, and at concentrations of 0.32-0.64 mM, it inhibits Vibrio alginolyticus. Gigantin B also demonstrates good heat resistance; after treatment at 90°C for 60 minutes, the minimum inhibitory concentration against the aforementioned microorganisms remains unchanged. In summary, the antimicrobial peptide Gigantin B possesses excellent antimicrobial properties, good heat stability, and low hemolytic activity, making it suitable as a polypeptide-based microbial inhibitor for applications in aquatic animal antimicrobial drugs, feed additives, immune enhancers, food preservatives, and pharmaceuticals. Attached Figure Description
[0013] Figure 1 This is a tertiary structure diagram of the antimicrobial peptide Gigantin B of the present invention;
[0014] Figure 2 This is a chromatogram of the HPLC detection results of the antimicrobial peptide Gigantin B of this invention;
[0015] Figure 3 This is a mass spectrometry detection result of the antimicrobial peptide Gigantin B of this invention;
[0016] Figure 4 This is a graph showing the detection results of the antimicrobial activity of the antimicrobial peptide Gigantin B against Vibrio. Numbers 1-7 represent the antimicrobial peptide concentrations as follows: 5.12 mM, 2.56 mM, 1.28 mM, 0.64 mM, 0.32 mM, 0.16 mM, and 0.08 mM, respectively. Negative control C: deionized water;
[0017] Figure 5 This is a graph showing the thermal stability test results of the antimicrobial peptide Gigantin B of this invention. P: Untreated antimicrobial peptide; C: Sterile water; Numbers 1-6 represent antimicrobial peptides treated at different temperatures and times. 1: 70℃ 30min; 2: 70℃ 60min; 3: 80℃ 30min; 4: 80℃ 60min; 5: 90℃ 30min; 6: 90℃ 60min;
[0018] Figure 6 This is the result of the determination of the hemolysis rate of crucian carp erythrocytes by the antimicrobial peptide Gigantin B of this invention. Detailed Implementation
[0019] The antimicrobial peptide Gigantopelta aegis, obtained from the deep-sea hydrothermal vent area of the Southwest Indian Ocean Ridge, was analyzed using its transcriptome data. The GigantinB gene, an antimicrobial peptide, was found in Gigantopelta aegis. Comparison with sequences in the APD3 antimicrobial peptide database revealed the highest sequence homology with BMP11 from *Lactobacillus crustorum* MN047 (35.71% sequence similarity), and 35% with an antimicrobial peptide from *Boleophthalmus pectinirostris*. The sequence similarity to Gigantin (patent number: ZL202310705663.2), a previously known antimicrobial peptide from the same source, was only 13.9%. Compared to Gigantin, GigantinB exhibits stronger inhibitory activity against aquatic pathogenic Vibrio bacteria and better thermostability.
[0020] The antimicrobial peptide GigantinB has an α-helical structure, consisting of 39 amino acid residues, with a molecular weight of 4,672 Da, an APD of 48%, a theoretical isoelectric point (PI) of 11.26, a net charge of +7.5, an overall average hydrophilicity of -0.108, and a high aliphatic index of 127.44.
[0021] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the embodiments do not limit the scope of the present invention.
[0022] Example 1: Screening and preparation of the antimicrobial peptide Gigantin B
[0023] The antimicrobial peptide GigantinB of this invention was screened from the transcriptome sequence data of the deep-sea hydrothermal vent benthic snail *Gigantinus spp.*. Nucleic acid sequences containing the antimicrobial peptide domain were screened based on PFAM annotation and then translated into amino acid sequences (SEQ ID No: 1). The physicochemical properties of the above amino acid sequence were analyzed using EMBOSS Programs and ProtParam. Tertiary structure analysis using the online tool AlphaFold3 showed that this peptide is a typical α-helix structure antimicrobial peptide. Figure 1 ).
[0024] The antimicrobial peptide with sequence SEQ ID No: 1 was prepared by Sangon Biotech (Shanghai) Co., Ltd. using a solid-phase chemical synthesis method. The synthesized antimicrobial peptide GigantinB was purified and analyzed by a semi-preparative high-performance liquid chromatography (HPLC) system, and its purity was ≥95%. Figure 2 The molecular weight of the obtained antimicrobial peptide was determined using liquid chromatography-mass spectrometry to confirm its identification as Gigantin B, the antimicrobial peptide of this invention. Figure 3 ).
[0025] Example 2: Analysis of the antibacterial activity of the antimicrobial peptide Gigantin B
[0026] The antimicrobial activity of the antimicrobial peptide Gigantin B was determined by the agar plate diffusion method. The tested microbial strains included Vibrio parahaemolyticus ATCC 17802 and Vibrio alginolyticus ATCC 17749, Vibrio alginolyticus S50-4 and Vibrio neocalidonia F82-1, all of which were laboratory-preserved strains.
[0027] Several types of Vibrio were inoculated into seawater LB agar at a 1% inoculation rate and incubated at 150 rpm in a shaker at 25°C until the OD600 value reached approximately 0.8. A cotton swab was used to apply the test bacterial suspension evenly onto the seawater LB agar plate. After the suspension was fully absorbed, the plate was divided into eight sections, with a sterile filter paper (6 mm in diameter) placed in the center of each section to ensure it was fully in contact with the culture medium. The lyophilized antimicrobial peptide Gigantin B was removed from the -80°C freezer and prepared into a 5.12 mM solution with deionized water. This solution was then successively diluted to 2.56 mM, 1.28 mM, 0.64 mM, 0.32 mM, 0.16 mM, and 0.08 mM. Take 15 μL of each antimicrobial peptide at different concentrations and slowly drop it onto filter paper to ensure even diffusion. Use deionized water as a negative control. After drying the plates, incubate them upside down overnight at 25°C. Measure the diameter of the inhibition zone to evaluate the antimicrobial activity of the antimicrobial peptides. Perform three parallel experiments for each test bacterium. Results are as follows: Figure 4 As shown, the antimicrobial peptide Gigantin B of the present invention exhibits good antibacterial activity against Vibrio alginolyticus, Vibrio neocalidonia, and Vibrio parahaemolyticus. At a concentration of 0.32 mM, it significantly inhibits Vibrio parahaemolyticus and Vibrio neocalidonia, and at concentrations of 0.32-0.64 mM, it inhibits Vibrio alginolyticus.
[0028] Example 3: Determination of the antibacterial rate of the antimicrobial peptide Gigantin B
[0029] The aforementioned pathogenic bacteria were inoculated into seawater LB medium and cultured overnight at 25°C with shaking. The cell concentration was then diluted to 1×10⁶ cells / mL with seawater LB medium. 5 CFU / mL. Then, 100 μL of the diluted bacterial culture was transferred to a 96-well plate. The antimicrobial peptide was dissolved in sterile water, and 100 μL was added to the bacterial culture in the 96-well plate to make the antimicrobial peptide concentrations in the bacterial culture 2.0 mM and 0.5 mM, respectively. After incubating the 96-well plate at 37℃ for 16 hours, bacterial growth was detected by a microplate reader. The sterile water plus bacterial culture group served as the positive control, and the sterile water diluted with seawater LB medium solution served as the blank control. The experiment was performed in triplicate. The inhibition rate was calculated as follows: Inhibition rate (%) = (OD... 600Positive control group - OD 600 (Antimicrobial peptide treatment group) / OD 600 Positive control group. Results are shown in Table 1.
[0030] Table 1. Inhibition rate of different concentrations of the antimicrobial peptide Gigantin B against pathogenic Vibrio.
[0031] 2.0 mM GigantinB 0.5 mM GigantinB Vibrio alginolyticus ATCC17749 69 % 10 % Vibrio parahaemolyticus ATCC17802 75 % 10 % New Caledonian Vibrio F82-1 82 % 14 % Vibrio alginolyticus S50-4 66 % 22 %
[0032] Example 4: Heat resistance analysis of the antimicrobial peptide Gigantin B
[0033] A 2.56 mM solution of the antimicrobial peptide Gigantin B was heated at 70℃, 80℃, and 90℃ for 30 min and 60 min, respectively. The antimicrobial activity was then analyzed using the plate diffusion method described above. The tested strain was *Vibrio alginolyticus* S50-4. Results are shown below. Figure 5 Treatment at 70–90℃ for 30–60 min showed no significant change in the diameter of the inhibition zone, indicating that the antimicrobial peptide activity remained stable. This demonstrates that the antimicrobial peptide Gigantin B, after high-temperature treatment, still maintains good antimicrobial activity and exhibits excellent thermal stability.
[0034] Example 5: Hemolytic Analysis of the Antimicrobial Peptide Gigantin B
[0035] Take 5 mL of fresh crucian carp blood, centrifuge at 1000 g for 5 minutes, discard the upper serum layer, collect the lower red blood cells, wash with phosphate-buffered saline (PBS) until the supernatant is colorless, and then prepare a 2% red blood cell suspension with PBS. Prepare the antimicrobial peptide Gigantin B at a concentration of 5.12 mM with PBS, and then dilute it 2-fold to 2.56 mM, 1.28 mM, 0.64 mM, and 0.32 mM. Add 100 μL of the different concentrations of antimicrobial peptide to each 1.5 mL EP tube, followed by 100 μL of the red blood cell suspension. Use PBS as a negative control (0% hemolysis) and 2% Tritonx-100 as a positive control (100% hemolysis). After incubating at room temperature for 30 minutes, centrifuge at 1000 g for 5 minutes. Add the supernatant sequentially to 96-well plates and measure the OD using a microplate reader. 570nm Value. According to the formula: Hemolysis rate (%) = (OD) 570nm Experimental group - OD 570nm Negative control group) / (OD 570nm Positive control group - OD 570nm The hemolysis rate was calculated using the negative control group. Figure 6It can be seen that as the concentration of antimicrobial peptide increases, its hemolytic activity also increases. At 2.56 mM, the hemolytic rate is about 33%, while at concentrations of 0.64 mM and below, its hemolytic activity is <5%, indicating that the antimicrobial peptide Gigantin B has high safety and can be applied to animal production.
Claims
1. An antimicrobial peptide, characterized in that the amino acid sequence of the antimicrobial peptide is SEQ ID NO:
1.
2. The use of the antimicrobial peptide according to claim 1 in the preparation of antimicrobial products.
3. Use according to claim 2, wherein the compound is ###0002### The antibacterial product is used for the prevention and treatment of Vibrio.
4. The application as described in claim 3, characterized in that, The Vibrio species mentioned are Vibrio parahaemolyticus, Vibrio alginolyticus, or Vibrio neocalidonia.
5. The use of the antimicrobial peptide according to claim 1 in the preparation of feed additives or immune enhancers.
6. An antibacterial product, characterized in that, The antimicrobial product contains the antimicrobial peptide as described in claim 1.
Citation Information
Patent Citations
Gigantin, an antimicrobial peptide from the deep-sea shield snail, and its application.
CN116640203B
